Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

Luping Lin, Saurabh Asthana, Elton Chan, Sourav Bandyopadhyay, Maria M. Martins, Victor Olivas, Jenny Jiacheng Yan, Luu Pham, Mingxue Michelle Wang, Gideon Bollag, David B. Solit, Eric A. Collisson, Charles M. Rudin, Barry S. Taylor, Trever G. Bivon

Research output: Contribution to journalArticle

Abstract

Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), accounting for more than 90,000 deaths annually worldwide. The biological and clinical relevance of these BRAF mutations in NSCLC is incompletely understood. Here we demonstrate that human NSCLC cells with BRAFV600E, but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment. However, these BRAFV600E NSCLC cells rapidly acquire resistance to BRAF inhibition through at least one of two discrete molecular mechanisms: (i) loss of full-length BRAFV600E coupled with expression of an aberrant form of BRAFV600E that retains RAF pathway dependence or (ii) constitutive autocrine EGF receptor (EGFR) signaling driven by c-Jun-mediated EGFR ligand expression. BRAFV600E cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor- resistant NSCLC clinical specimens. These data reveal the multifaceted molecular mechanisms by which NSCLCs establish and regulate BRAF oncogene dependence, provide insights into BRAF- EGFR signaling crosstalk, and uncover mechanism-based strategies to optimize clinical responses to BRAF oncogene inhibition.

Original languageEnglish (US)
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number7
DOIs
StatePublished - Feb 18 2014
Externally publishedYes

Fingerprint

Oncogenes
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Epidermal Growth Factor Receptor
Mutation
Proto-Oncogene Proteins B-raf
Protein Kinases
Biomarkers

Keywords

  • Combination therapy
  • Targeted therapy

ASJC Scopus subject areas

  • General

Cite this

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. / Lin, Luping; Asthana, Saurabh; Chan, Elton; Bandyopadhyay, Sourav; Martins, Maria M.; Olivas, Victor; Yan, Jenny Jiacheng; Pham, Luu; Wang, Mingxue Michelle; Bollag, Gideon; Solit, David B.; Collisson, Eric A.; Rudin, Charles M.; Taylor, Barry S.; Bivon, Trever G.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 7, 18.02.2014.

Research output: Contribution to journalArticle

Lin, L, Asthana, S, Chan, E, Bandyopadhyay, S, Martins, MM, Olivas, V, Yan, JJ, Pham, L, Wang, MM, Bollag, G, Solit, DB, Collisson, EA, Rudin, CM, Taylor, BS & Bivon, TG 2014, 'Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 7. https://doi.org/10.1073/pnas.1320956111/-/DCSupplemental
Lin, Luping ; Asthana, Saurabh ; Chan, Elton ; Bandyopadhyay, Sourav ; Martins, Maria M. ; Olivas, Victor ; Yan, Jenny Jiacheng ; Pham, Luu ; Wang, Mingxue Michelle ; Bollag, Gideon ; Solit, David B. ; Collisson, Eric A. ; Rudin, Charles M. ; Taylor, Barry S. ; Bivon, Trever G. / Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 7.
@article{a128439086a645af8cb1e5c1fa51323f,
title = "Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer",
abstract = "Oncogenic mutations in the BRAF kinase occur in 6-8{\%} of nonsmall cell lung cancers (NSCLCs), accounting for more than 90,000 deaths annually worldwide. The biological and clinical relevance of these BRAF mutations in NSCLC is incompletely understood. Here we demonstrate that human NSCLC cells with BRAFV600E, but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment. However, these BRAFV600E NSCLC cells rapidly acquire resistance to BRAF inhibition through at least one of two discrete molecular mechanisms: (i) loss of full-length BRAFV600E coupled with expression of an aberrant form of BRAFV600E that retains RAF pathway dependence or (ii) constitutive autocrine EGF receptor (EGFR) signaling driven by c-Jun-mediated EGFR ligand expression. BRAFV600E cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor- resistant NSCLC clinical specimens. These data reveal the multifaceted molecular mechanisms by which NSCLCs establish and regulate BRAF oncogene dependence, provide insights into BRAF- EGFR signaling crosstalk, and uncover mechanism-based strategies to optimize clinical responses to BRAF oncogene inhibition.",
keywords = "Combination therapy, Targeted therapy",
author = "Luping Lin and Saurabh Asthana and Elton Chan and Sourav Bandyopadhyay and Martins, {Maria M.} and Victor Olivas and Yan, {Jenny Jiacheng} and Luu Pham and Wang, {Mingxue Michelle} and Gideon Bollag and Solit, {David B.} and Collisson, {Eric A.} and Rudin, {Charles M.} and Taylor, {Barry S.} and Bivon, {Trever G.}",
year = "2014",
month = "2",
day = "18",
doi = "10.1073/pnas.1320956111/-/DCSupplemental",
language = "English (US)",
volume = "111",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

AU - Lin, Luping

AU - Asthana, Saurabh

AU - Chan, Elton

AU - Bandyopadhyay, Sourav

AU - Martins, Maria M.

AU - Olivas, Victor

AU - Yan, Jenny Jiacheng

AU - Pham, Luu

AU - Wang, Mingxue Michelle

AU - Bollag, Gideon

AU - Solit, David B.

AU - Collisson, Eric A.

AU - Rudin, Charles M.

AU - Taylor, Barry S.

AU - Bivon, Trever G.

PY - 2014/2/18

Y1 - 2014/2/18

N2 - Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), accounting for more than 90,000 deaths annually worldwide. The biological and clinical relevance of these BRAF mutations in NSCLC is incompletely understood. Here we demonstrate that human NSCLC cells with BRAFV600E, but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment. However, these BRAFV600E NSCLC cells rapidly acquire resistance to BRAF inhibition through at least one of two discrete molecular mechanisms: (i) loss of full-length BRAFV600E coupled with expression of an aberrant form of BRAFV600E that retains RAF pathway dependence or (ii) constitutive autocrine EGF receptor (EGFR) signaling driven by c-Jun-mediated EGFR ligand expression. BRAFV600E cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor- resistant NSCLC clinical specimens. These data reveal the multifaceted molecular mechanisms by which NSCLCs establish and regulate BRAF oncogene dependence, provide insights into BRAF- EGFR signaling crosstalk, and uncover mechanism-based strategies to optimize clinical responses to BRAF oncogene inhibition.

AB - Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), accounting for more than 90,000 deaths annually worldwide. The biological and clinical relevance of these BRAF mutations in NSCLC is incompletely understood. Here we demonstrate that human NSCLC cells with BRAFV600E, but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment. However, these BRAFV600E NSCLC cells rapidly acquire resistance to BRAF inhibition through at least one of two discrete molecular mechanisms: (i) loss of full-length BRAFV600E coupled with expression of an aberrant form of BRAFV600E that retains RAF pathway dependence or (ii) constitutive autocrine EGF receptor (EGFR) signaling driven by c-Jun-mediated EGFR ligand expression. BRAFV600E cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor- resistant NSCLC clinical specimens. These data reveal the multifaceted molecular mechanisms by which NSCLCs establish and regulate BRAF oncogene dependence, provide insights into BRAF- EGFR signaling crosstalk, and uncover mechanism-based strategies to optimize clinical responses to BRAF oncogene inhibition.

KW - Combination therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84894300510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894300510&partnerID=8YFLogxK

U2 - 10.1073/pnas.1320956111/-/DCSupplemental

DO - 10.1073/pnas.1320956111/-/DCSupplemental

M3 - Article

C2 - 24550319

AN - SCOPUS:84894300510

VL - 111

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -